Effective therapeutic vaccination against tumors depends on the design and screening of a high-quality tumor antigen, efficient antigen uptake by DCs, the sustained activation of CD4+ T cells and CD8+ T cells, T-cell infiltration into the TME and the strong persistence of the immune response. This evidence concerns the gene CD8A and neoplasm.